• Profile
Close

Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups

American Journal of Clinical Dermatology Oct 03, 2019

Callender VD, Alexis AF, Gold LFS, et al. - In this investigation, researchers tested the safety and effectiveness of crisaborole ointment, 2%, depending on race [Asian/native Hawaiian/other Pacific Islander, black/African American, and other/American Indian/Alaskan native] and ethnicity [Hispanic/Latino or not Hispanic/Latino] for the treatment of mild-to-moderate atopic dermatitis (AD) in individuals aged ≥ 2 years. In the pivotal trials, the frequency of crisaborole-related adverse events was 7.1–8.5%. Regardless of race or ethnicity, in patients aged ≥ 2 years with mild-to-moderate AD, crisaborole improved global disease severity. Crisaborole has been effective in decreasing AD signs prevalent in patients with color skin and has been associated with low frequency treatment-related treatment-emergent adverse events, indicating that crisaborole may be a suitable treatment choice for these patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay